JO
DYN icon

John Overdeck’s Dyne Therapeutics DYN Stock Holding History

John Overdeck’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$315K Buy
+14,178
New +$264K ﹤0.01% 4488
2024
Q3 		– Sell
-159,154
Closed -$5.62M – 3163
2024
Q2 		$5.62M Buy
159,154
+150,242
+1,686% +$4.37M 0.01% 956
2024
Q1 		$253K Buy
+8,912
New +$202K ﹤0.01% 2623
2023
Q4 		– Sell
-24,400
Closed -$219K – 3206
2023
Q3 		$219K Sell
24,400
-8,100
-25% -$87.2K ﹤0.01% 2605
2023
Q2 		$366K Sell
32,500
-126,487
-80% -$1.49M ﹤0.01% 2459
2023
Q1 		$1.83M Buy
158,987
+3,638
+2% +$47.2K 0.01% 1430
2022
Q4 		$1.8M Buy
155,349
+138,325
+813% +$1.6M 0.01% 1365
2022
Q3 		$216K Buy
+17,024
New +$195K ﹤0.01% 2082
2022
Q2 		– Sell
-26,722
Closed -$258K – 2618
2022
Q1 		$258K Sell
26,722
-101,007
-79% -$860K ﹤0.01% 2268
2021
Q4 		$1.52M Buy
127,729
+14,525
+13% +$204K ﹤0.01% 2181
2021
Q3 		$1.84M Buy
+113,204
New +$2.01M ﹤0.01% 2067
2021
Q2 		– Sell
-26,000
Closed -$404K – 4155
2021
Q1 		$404K Buy
+26,000
New +$503K ﹤0.01% 3115

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

John Overdeck's DYN Position: Q2 2026 in Review

John Overdeck opened a new position in Dyne Therapeutics (DYN) in Q2 2026: 14,178 shares worth $315K. The stake represents ﹤0.01% of the portfolio and ranks #4488 among its holdings. This is a return to the name: John Overdeck previously reported a position in DYN as recently as Q2 2024.

John Overdeck first reported a position in DYN in Q1 2021 and has held it in 12 quarters since. The position peaked at $5.62M in Q2 2024. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • John Overdeck held 14,178 shares of Dyne Therapeutics worth $315K as of Q2 2026.
  • Dyne Therapeutics was a new John Overdeck position in Q2 2026.
  • Dyne Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4488 holding.
  • John Overdeck first reported a position in Dyne Therapeutics in Q1 2021 and has held it in 12 quarters since.
  • John Overdeck's Dyne Therapeutics position peaked at $5.62M in Q2 2024.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.